On April 28th, all official patient communication groups owned by Xiaohe Health under Beijing-based tech giant ByteDance will cease operations due to business adjustments. In February, rumors circulated that the Xiaohe Health App would be shut down.
At the beginning of this year, ByteDance's short video app Douyin started to explore online livestream broadcasting as a method of promoting and facilitating drug sales.
Junshi Biosciences, a Chinese biopharmaceutical company, announced on January 18 that the country's medical products authorities had accepted a new drug application for Deuremidevir Hydrobromide Tablets (project code: JT001/VV116) for the treatment of COVID-19.
Hangzhou-based tech giant Alibaba has launched a special campaign to provide free COVID-19 consultation services for rural areas, support the training of grassroots medical staff, and donate urgently needed medicines and medical devices to 22 underdeveloped counties across the country.
On December 4, an article entitled "Real-Name Report on Inaccurate Nucleic Acid Testing by BGI" was widely spread on the Chinese internet. In the piece, a man with username "Wang Deming" reported that nucleic acid COVID-19 tests conducted by Chinese genomics company BGI were inaccurate.
Recently, Chinese nucleic acid testing companies have been controversial and accused of making huge profits during the COVID-19 pandemic. Among them, a company called Nucleus Gene has aroused widespread public doubts.
Yuyue Medical, a Chinese medical device manufacturer, announced on September 19 that internet giant Tencent plans to invest 291 million yuan ($41.5 million) in its subsidiary, Xunjie Medical.
China's National Medical Products Administration granted approval on August 31 to Tencent Healthcare (Shenzhen) Co., Ltd. for the registration of its innovative medical device.
